Table 3.
List of clinical trials available for asparaginase encapsulated in erythrocytes (Eryaspase).
| Clinicaltrial.gov Identifier | NCT03674242 | NCT03665441 | NCT02195180 | NCT03267030 |
|---|---|---|---|---|
| Drug encapsulated in erythrocyte | Asparaginase encapsulated in erythrocytes (Eryaspase) | |||
| Eryaspase combined with other anti-cancer drugs | Eryaspase combined with gemcitabine or carboplatin | Eryaspase combined with either gemcitabine plus abraxane, or irinotecan-based therapy | Eryaspase combined with gemcitabine or 5-fluoro-uracil/oxaliplatin/leucovorin (FOLFOX) | Eryaspase combined with GRASPA |
| Purpose | Treatment | Treatment | Treatment | Treatment |
| Cancer type | Triple negative breast cancer | Pancreatic adenocarcinoma | Progressive metastatic pancreatic carcinoma | Acute lymphoblastic leukemia |
| Recruitment status | Recruiting | Active, not recruiting | Completed | Completed |
| Sponsor | ERYtech Pharma | ERYtech Pharma | ERYtech Pharma | Birgitte Klug Albertsen |
| Study-type | Interventional | Interventional | Interventional | Interventional |
| No of participants | 64 | 500 | 141 | 55 |
| Allocation | Randomized | Randomized | Randomized | N/A |
| Intervention model | Parallel assignment | Parallel assignment | Parallel assignment | Single group assignment |
| Masking | Open label | Open label | Open label | Open label |
| Phase | Phase 2/3 | Phase 3 | Phase 2 | Phase 2 |
| Start of the study | June 2019 | September 2018 | July 2014 | August 2017 |
| Completion of the study | October 2020 | October 2021 | November 2017 | October 2020 |